Abstract
PD-1/PD-Ls is an inhibitory signaling pathway involved in tumor immune evasion. Human PD-1 antibody is a method for treating tumors, which can block the interaction between PD-L1 and PD-1 to maintain the activation state of T lymphocytes that destroy tumors.In order to obtain high quality human PD-1 antibody, we prepared sPD-1, cell containing mPD-1 and cell membrane enrichment containing mPD-1, the New Zealand white rabbits immunized with three type immunogen respectively, and initially compare the titer and specificity of antibodies in serum of Immunized rabbit. The experiment showed that the mPD-1 antibodies titer was slightly lower than sPD-1 antibody, but the mPD-1 antibodies showed more high specificity in the experiments of antibody specificity by western blotting and indirect ELISA.Cell containing mPD-1 and mPD-1 membrane enrichment have similar immune effects, but cell containing mPD-1, which is easier to handle, may be more suitable for immunizing animals to obtain antibodies.
Keywords
Full Text:
References
Turkson, J. in The Molecular Basis of Human Cancer. (eds. W.B. Coleman & G.J. Tsongalis) 695-707 (Springer New York, New York, NY; 2017).
Copur, M.S., Ramaekers, R. & Crockett, D. Ipilimumab Adjuvant Therapy in Melanoma. New England Journal of Medicine. 2017:376, 398-399.
Guan, J., Lim, K.S., Mekhail, T. & Chang, C.C. Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. Archives of pathology & laboratory medicine (2017).
Syn, N.L., Teng, M.W.L., Mok, T.S.K. & Soo, R.A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncology. 2017;18, e731-e741.
Fife, B.T. & Pauken, K.E. The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences. 2011;1217:45-59.
Plimack, E.R. et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology. 2017;18:212-220.
Pellegrino, B., Musolino, A. & Tiseo, M. Anti-PD-1-Related Cryoglobulinemia during treatment with nivolumab in NSCLC patient. Annals of oncology: official journal of the European Society for Medical Oncology (2017).
Robert, C. et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. New England Journal of Medicine. 2011;364: 2517-2526.
Gao, J.J., Bernatchez, C., Sharma, P., Radvanyi, L.G. & Hwu, P. Advances in the development of cancer. immunotherapies. Trends in Immunology. 2013;34:90-98.
Puszkiel, A. et al. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of pharmaceutical and biomedical analysis.2017;139:30-36.
Muller, M., Schouten, R.D., De Gooijer, C.J. & Baas, P. Pembrolizumab for the treatment of non-small cell lung cancer. Expert review of anticancer therapy. 2017:1-11.
De Maeseneer, D.J., Delafontaine, B. & Rottey, S. Checkpoint inhibition: new treatment options in urologic cancer. Acta clinica Belgica.2017; 72:24-28.
Raja et al. PD-1 induction through TCR activation is partially regulated by endogenous TGF-?. Cellular & Molecular Immunology. 2015; 648-649.
Xu, J. et al. Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. American Journal of Surgical Pathology. 2016;40:443-453.
Schreiner, B., Bailey, S., T, Chen, L. & Miller, S. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. European journal of immunology. 2010;38:2706-2717.
Blank, C. et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2014;64:1140-1145.
Francisco, L.M., Sage, P.T. & Sharpe, A.H. The PD-1 Pathway in Tolerance and Autoimmunity. Immunological Reviews. 2010;236, 219-242.
Donahue, R.N. et al. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. Journal for Immunotherapy of Cancer. 5 (2017).
Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America.2017;104:3360-3365.
Thompson, R.H. et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Journal of Urology. 2005; 173:169-169..
Dieterich, L.C. et al. Tumor-Associated Lymphatic Vessels Upregulate PDL1 to Inhibit T-Cell Activation. Frontiers in immunology. 2017;8: 66.
Okazaki, T. & Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. International Immunology. 2007;19:813-824.
Philips, G.K. & Atkins, M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. International Immunology. 2015;27:39-46.
Taube, J.M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Science translational medicine. 4;2012;127ra137.
Wajant, H., et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001;20:4101-4106.
Roybal, K. et al. Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016;167, 419-432.e416.
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.